Cargando…
A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma
The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 p...
Autores principales: | Horwich, A, Oliver, R T D, Wilkinson, P M, Mead, G M, Harland, S J, Cullen, M H, Roberts, J T, Fossa, S D, Dearnaley, D P, Lallemand, E, Stenning, S P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363456/ https://www.ncbi.nlm.nih.gov/pubmed/11104556 http://dx.doi.org/10.1054/bjoc.2000.1498 |
Ejemplares similares
-
Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma
por: Horwich, A, et al.
Publicado: (2014) -
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
por: Bokemeyer, C, et al.
Publicado: (2004) -
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999) -
Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17)
por: Dearnaley, D P, et al.
Publicado: (2005) -
Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604)
por: Cafferty, Fay H., et al.
Publicado: (2020)